Phase II study of a gemcitabine and cisplatin combination regimen in taxane resistant metastatic breast cancer
To determine the safety and efficacy of gemcitabine and cisplatin in patients with taxane resistant metastatic breast cancer. Thirty-three taxane resistant metastatic breast cancer patients were treated with gemcitabine 1,250 mg/m2 IV infusion over 30 min on days 1 and 8, and with cisplatin 75 mg/m2...
Gespeichert in:
Veröffentlicht in: | Cancer chemotherapy and pharmacology 2007-02, Vol.59 (2), p.269-274 |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 274 |
---|---|
container_issue | 2 |
container_start_page | 269 |
container_title | Cancer chemotherapy and pharmacology |
container_volume | 59 |
creator | JAE HONG SEO SANG CHEUL OH CHEUL WON CHOI BYUNG SOO KIM SANG WON SHIN YEUL HONG KIM JUN SUK KIM KIM, Ae-Ree LEE, Jae-Bok BUM HWAN KOO |
description | To determine the safety and efficacy of gemcitabine and cisplatin in patients with taxane resistant metastatic breast cancer.
Thirty-three taxane resistant metastatic breast cancer patients were treated with gemcitabine 1,250 mg/m2 IV infusion over 30 min on days 1 and 8, and with cisplatin 75 mg/m2 by IV infusion over 1 h on day 1 in 21 day cycles.
Of the 30 evaluable patients, there were 9 (30%) partial responses and no complete response, an overall objective response rate of 30%. Median time to progression and median survival duration for all study subjects were 7 (95% CI 5.1-8.9 months) and 15 months (95% CI 10.5-19.5 months), respectively. Toxicities included grade 3 and 4 leucopenia in 10 (30%), thrombocytopenia in 6 (18%), anemia in 2 (6%) and oral mucositis in 2 (6%). No grade 3 or 4 peripheral neuropathy, renal dysfunction, hepatic dysfunction, or nausea/vomiting was observed, and no treatment-related deaths occurred.
The described gemcitabine plus cisplatin combination was found to be an active and tolerable salvage regimen in patients with taxane resistant metastatic breast cancer. |
doi_str_mv | 10.1007/s00280-006-0266-x |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_213504465</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1192435411</sourcerecordid><originalsourceid>FETCH-LOGICAL-c356t-ffb85e03a9c72edd4691f85c1402c24b73ec4c8a738d2cfec2727ee38ae970ae3</originalsourceid><addsrcrecordid>eNpFkE1LBDEMhosoun78AC9SBI-j6cdMZ48ifiwIetBzyXQyWtnprG0X1n9vZRc85SU8ScjD2LmAawFgbhKAbKECaCqQTVNt9thMaCUraLXaZzNQWle1AX3EjlP6AgAtlDpkR6IxjTJzMWPh9RMT8cWCp7zuf_g0cOQfNDqfsfOBOIaeO59WS8w-cDeNpVviFHikDz9S4KWdcYOFjZR8yhgyHyljSdk73kUqkTsMjuIpOxhwmehsV0_Y-8P9291T9fzyuLi7fa6cqptcDUPX1gQK585I6nvdzMXQ1k5okE7qzihy2rVoVNtLN5CTRhoi1SLNDSCpE3a53buK0_eaUrZf0zqGctJKoWrQuqkLJLaQi1NKkQa7in7E-GMF2D_BdivYFsH2T7DdlJmL3eJ1N1L_P7EzWoCrHYDJ4XKI5W-f_rlWQ6FA_QKK0YUH</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>213504465</pqid></control><display><type>article</type><title>Phase II study of a gemcitabine and cisplatin combination regimen in taxane resistant metastatic breast cancer</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>JAE HONG SEO ; SANG CHEUL OH ; CHEUL WON CHOI ; BYUNG SOO KIM ; SANG WON SHIN ; YEUL HONG KIM ; JUN SUK KIM ; KIM, Ae-Ree ; LEE, Jae-Bok ; BUM HWAN KOO</creator><creatorcontrib>JAE HONG SEO ; SANG CHEUL OH ; CHEUL WON CHOI ; BYUNG SOO KIM ; SANG WON SHIN ; YEUL HONG KIM ; JUN SUK KIM ; KIM, Ae-Ree ; LEE, Jae-Bok ; BUM HWAN KOO</creatorcontrib><description>To determine the safety and efficacy of gemcitabine and cisplatin in patients with taxane resistant metastatic breast cancer.
Thirty-three taxane resistant metastatic breast cancer patients were treated with gemcitabine 1,250 mg/m2 IV infusion over 30 min on days 1 and 8, and with cisplatin 75 mg/m2 by IV infusion over 1 h on day 1 in 21 day cycles.
Of the 30 evaluable patients, there were 9 (30%) partial responses and no complete response, an overall objective response rate of 30%. Median time to progression and median survival duration for all study subjects were 7 (95% CI 5.1-8.9 months) and 15 months (95% CI 10.5-19.5 months), respectively. Toxicities included grade 3 and 4 leucopenia in 10 (30%), thrombocytopenia in 6 (18%), anemia in 2 (6%) and oral mucositis in 2 (6%). No grade 3 or 4 peripheral neuropathy, renal dysfunction, hepatic dysfunction, or nausea/vomiting was observed, and no treatment-related deaths occurred.
The described gemcitabine plus cisplatin combination was found to be an active and tolerable salvage regimen in patients with taxane resistant metastatic breast cancer.</description><identifier>ISSN: 0344-5704</identifier><identifier>EISSN: 1432-0843</identifier><identifier>DOI: 10.1007/s00280-006-0266-x</identifier><identifier>PMID: 16763791</identifier><identifier>CODEN: CCPHDZ</identifier><language>eng</language><publisher>Berlin: Springer</publisher><subject>Adult ; Aged ; Alopecia - chemically induced ; Anemia - chemically induced ; Antimetabolites, Antineoplastic - adverse effects ; Antimetabolites, Antineoplastic - therapeutic use ; Antineoplastic agents ; Biological and medical sciences ; Breast Neoplasms - drug therapy ; Breast Neoplasms - pathology ; Bridged-Ring Compounds - administration & dosage ; Cisplatin - administration & dosage ; Cisplatin - adverse effects ; Deoxycytidine - administration & dosage ; Deoxycytidine - adverse effects ; Deoxycytidine - analogs & derivatives ; Disease Progression ; Drug Administration Schedule ; Drug Resistance, Neoplasm - drug effects ; Female ; Gynecology. Andrology. Obstetrics ; Humans ; Infusions, Intravenous ; Leukopenia - chemically induced ; Mammary gland diseases ; Medical sciences ; Middle Aged ; Neoplasm Metastasis ; Pharmacology. Drug treatments ; Recurrence ; Severity of Illness Index ; Stomatitis - chemically induced ; Survival Rate ; Taxoids - administration & dosage ; Thrombocytopenia - chemically induced ; Treatment Outcome ; Tumors</subject><ispartof>Cancer chemotherapy and pharmacology, 2007-02, Vol.59 (2), p.269-274</ispartof><rights>2007 INIST-CNRS</rights><rights>Springer-Verlag 2007</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c356t-ffb85e03a9c72edd4691f85c1402c24b73ec4c8a738d2cfec2727ee38ae970ae3</citedby><cites>FETCH-LOGICAL-c356t-ffb85e03a9c72edd4691f85c1402c24b73ec4c8a738d2cfec2727ee38ae970ae3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18409130$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16763791$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>JAE HONG SEO</creatorcontrib><creatorcontrib>SANG CHEUL OH</creatorcontrib><creatorcontrib>CHEUL WON CHOI</creatorcontrib><creatorcontrib>BYUNG SOO KIM</creatorcontrib><creatorcontrib>SANG WON SHIN</creatorcontrib><creatorcontrib>YEUL HONG KIM</creatorcontrib><creatorcontrib>JUN SUK KIM</creatorcontrib><creatorcontrib>KIM, Ae-Ree</creatorcontrib><creatorcontrib>LEE, Jae-Bok</creatorcontrib><creatorcontrib>BUM HWAN KOO</creatorcontrib><title>Phase II study of a gemcitabine and cisplatin combination regimen in taxane resistant metastatic breast cancer</title><title>Cancer chemotherapy and pharmacology</title><addtitle>Cancer Chemother Pharmacol</addtitle><description>To determine the safety and efficacy of gemcitabine and cisplatin in patients with taxane resistant metastatic breast cancer.
Thirty-three taxane resistant metastatic breast cancer patients were treated with gemcitabine 1,250 mg/m2 IV infusion over 30 min on days 1 and 8, and with cisplatin 75 mg/m2 by IV infusion over 1 h on day 1 in 21 day cycles.
Of the 30 evaluable patients, there were 9 (30%) partial responses and no complete response, an overall objective response rate of 30%. Median time to progression and median survival duration for all study subjects were 7 (95% CI 5.1-8.9 months) and 15 months (95% CI 10.5-19.5 months), respectively. Toxicities included grade 3 and 4 leucopenia in 10 (30%), thrombocytopenia in 6 (18%), anemia in 2 (6%) and oral mucositis in 2 (6%). No grade 3 or 4 peripheral neuropathy, renal dysfunction, hepatic dysfunction, or nausea/vomiting was observed, and no treatment-related deaths occurred.
The described gemcitabine plus cisplatin combination was found to be an active and tolerable salvage regimen in patients with taxane resistant metastatic breast cancer.</description><subject>Adult</subject><subject>Aged</subject><subject>Alopecia - chemically induced</subject><subject>Anemia - chemically induced</subject><subject>Antimetabolites, Antineoplastic - adverse effects</subject><subject>Antimetabolites, Antineoplastic - therapeutic use</subject><subject>Antineoplastic agents</subject><subject>Biological and medical sciences</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - pathology</subject><subject>Bridged-Ring Compounds - administration & dosage</subject><subject>Cisplatin - administration & dosage</subject><subject>Cisplatin - adverse effects</subject><subject>Deoxycytidine - administration & dosage</subject><subject>Deoxycytidine - adverse effects</subject><subject>Deoxycytidine - analogs & derivatives</subject><subject>Disease Progression</subject><subject>Drug Administration Schedule</subject><subject>Drug Resistance, Neoplasm - drug effects</subject><subject>Female</subject><subject>Gynecology. Andrology. Obstetrics</subject><subject>Humans</subject><subject>Infusions, Intravenous</subject><subject>Leukopenia - chemically induced</subject><subject>Mammary gland diseases</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neoplasm Metastasis</subject><subject>Pharmacology. Drug treatments</subject><subject>Recurrence</subject><subject>Severity of Illness Index</subject><subject>Stomatitis - chemically induced</subject><subject>Survival Rate</subject><subject>Taxoids - administration & dosage</subject><subject>Thrombocytopenia - chemically induced</subject><subject>Treatment Outcome</subject><subject>Tumors</subject><issn>0344-5704</issn><issn>1432-0843</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNpFkE1LBDEMhosoun78AC9SBI-j6cdMZ48ifiwIetBzyXQyWtnprG0X1n9vZRc85SU8ScjD2LmAawFgbhKAbKECaCqQTVNt9thMaCUraLXaZzNQWle1AX3EjlP6AgAtlDpkR6IxjTJzMWPh9RMT8cWCp7zuf_g0cOQfNDqfsfOBOIaeO59WS8w-cDeNpVviFHikDz9S4KWdcYOFjZR8yhgyHyljSdk73kUqkTsMjuIpOxhwmehsV0_Y-8P9291T9fzyuLi7fa6cqptcDUPX1gQK585I6nvdzMXQ1k5okE7qzihy2rVoVNtLN5CTRhoi1SLNDSCpE3a53buK0_eaUrZf0zqGctJKoWrQuqkLJLaQi1NKkQa7in7E-GMF2D_BdivYFsH2T7DdlJmL3eJ1N1L_P7EzWoCrHYDJ4XKI5W-f_rlWQ6FA_QKK0YUH</recordid><startdate>20070201</startdate><enddate>20070201</enddate><creator>JAE HONG SEO</creator><creator>SANG CHEUL OH</creator><creator>CHEUL WON CHOI</creator><creator>BYUNG SOO KIM</creator><creator>SANG WON SHIN</creator><creator>YEUL HONG KIM</creator><creator>JUN SUK KIM</creator><creator>KIM, Ae-Ree</creator><creator>LEE, Jae-Bok</creator><creator>BUM HWAN KOO</creator><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20070201</creationdate><title>Phase II study of a gemcitabine and cisplatin combination regimen in taxane resistant metastatic breast cancer</title><author>JAE HONG SEO ; SANG CHEUL OH ; CHEUL WON CHOI ; BYUNG SOO KIM ; SANG WON SHIN ; YEUL HONG KIM ; JUN SUK KIM ; KIM, Ae-Ree ; LEE, Jae-Bok ; BUM HWAN KOO</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c356t-ffb85e03a9c72edd4691f85c1402c24b73ec4c8a738d2cfec2727ee38ae970ae3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Alopecia - chemically induced</topic><topic>Anemia - chemically induced</topic><topic>Antimetabolites, Antineoplastic - adverse effects</topic><topic>Antimetabolites, Antineoplastic - therapeutic use</topic><topic>Antineoplastic agents</topic><topic>Biological and medical sciences</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - pathology</topic><topic>Bridged-Ring Compounds - administration & dosage</topic><topic>Cisplatin - administration & dosage</topic><topic>Cisplatin - adverse effects</topic><topic>Deoxycytidine - administration & dosage</topic><topic>Deoxycytidine - adverse effects</topic><topic>Deoxycytidine - analogs & derivatives</topic><topic>Disease Progression</topic><topic>Drug Administration Schedule</topic><topic>Drug Resistance, Neoplasm - drug effects</topic><topic>Female</topic><topic>Gynecology. Andrology. Obstetrics</topic><topic>Humans</topic><topic>Infusions, Intravenous</topic><topic>Leukopenia - chemically induced</topic><topic>Mammary gland diseases</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neoplasm Metastasis</topic><topic>Pharmacology. Drug treatments</topic><topic>Recurrence</topic><topic>Severity of Illness Index</topic><topic>Stomatitis - chemically induced</topic><topic>Survival Rate</topic><topic>Taxoids - administration & dosage</topic><topic>Thrombocytopenia - chemically induced</topic><topic>Treatment Outcome</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>JAE HONG SEO</creatorcontrib><creatorcontrib>SANG CHEUL OH</creatorcontrib><creatorcontrib>CHEUL WON CHOI</creatorcontrib><creatorcontrib>BYUNG SOO KIM</creatorcontrib><creatorcontrib>SANG WON SHIN</creatorcontrib><creatorcontrib>YEUL HONG KIM</creatorcontrib><creatorcontrib>JUN SUK KIM</creatorcontrib><creatorcontrib>KIM, Ae-Ree</creatorcontrib><creatorcontrib>LEE, Jae-Bok</creatorcontrib><creatorcontrib>BUM HWAN KOO</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Cancer chemotherapy and pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>JAE HONG SEO</au><au>SANG CHEUL OH</au><au>CHEUL WON CHOI</au><au>BYUNG SOO KIM</au><au>SANG WON SHIN</au><au>YEUL HONG KIM</au><au>JUN SUK KIM</au><au>KIM, Ae-Ree</au><au>LEE, Jae-Bok</au><au>BUM HWAN KOO</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Phase II study of a gemcitabine and cisplatin combination regimen in taxane resistant metastatic breast cancer</atitle><jtitle>Cancer chemotherapy and pharmacology</jtitle><addtitle>Cancer Chemother Pharmacol</addtitle><date>2007-02-01</date><risdate>2007</risdate><volume>59</volume><issue>2</issue><spage>269</spage><epage>274</epage><pages>269-274</pages><issn>0344-5704</issn><eissn>1432-0843</eissn><coden>CCPHDZ</coden><abstract>To determine the safety and efficacy of gemcitabine and cisplatin in patients with taxane resistant metastatic breast cancer.
Thirty-three taxane resistant metastatic breast cancer patients were treated with gemcitabine 1,250 mg/m2 IV infusion over 30 min on days 1 and 8, and with cisplatin 75 mg/m2 by IV infusion over 1 h on day 1 in 21 day cycles.
Of the 30 evaluable patients, there were 9 (30%) partial responses and no complete response, an overall objective response rate of 30%. Median time to progression and median survival duration for all study subjects were 7 (95% CI 5.1-8.9 months) and 15 months (95% CI 10.5-19.5 months), respectively. Toxicities included grade 3 and 4 leucopenia in 10 (30%), thrombocytopenia in 6 (18%), anemia in 2 (6%) and oral mucositis in 2 (6%). No grade 3 or 4 peripheral neuropathy, renal dysfunction, hepatic dysfunction, or nausea/vomiting was observed, and no treatment-related deaths occurred.
The described gemcitabine plus cisplatin combination was found to be an active and tolerable salvage regimen in patients with taxane resistant metastatic breast cancer.</abstract><cop>Berlin</cop><pub>Springer</pub><pmid>16763791</pmid><doi>10.1007/s00280-006-0266-x</doi><tpages>6</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0344-5704 |
ispartof | Cancer chemotherapy and pharmacology, 2007-02, Vol.59 (2), p.269-274 |
issn | 0344-5704 1432-0843 |
language | eng |
recordid | cdi_proquest_journals_213504465 |
source | MEDLINE; SpringerLink Journals - AutoHoldings |
subjects | Adult Aged Alopecia - chemically induced Anemia - chemically induced Antimetabolites, Antineoplastic - adverse effects Antimetabolites, Antineoplastic - therapeutic use Antineoplastic agents Biological and medical sciences Breast Neoplasms - drug therapy Breast Neoplasms - pathology Bridged-Ring Compounds - administration & dosage Cisplatin - administration & dosage Cisplatin - adverse effects Deoxycytidine - administration & dosage Deoxycytidine - adverse effects Deoxycytidine - analogs & derivatives Disease Progression Drug Administration Schedule Drug Resistance, Neoplasm - drug effects Female Gynecology. Andrology. Obstetrics Humans Infusions, Intravenous Leukopenia - chemically induced Mammary gland diseases Medical sciences Middle Aged Neoplasm Metastasis Pharmacology. Drug treatments Recurrence Severity of Illness Index Stomatitis - chemically induced Survival Rate Taxoids - administration & dosage Thrombocytopenia - chemically induced Treatment Outcome Tumors |
title | Phase II study of a gemcitabine and cisplatin combination regimen in taxane resistant metastatic breast cancer |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T14%3A58%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Phase%20II%20study%20of%20a%20gemcitabine%20and%20cisplatin%20combination%20regimen%20in%20taxane%20resistant%20metastatic%20breast%20cancer&rft.jtitle=Cancer%20chemotherapy%20and%20pharmacology&rft.au=JAE%20HONG%20SEO&rft.date=2007-02-01&rft.volume=59&rft.issue=2&rft.spage=269&rft.epage=274&rft.pages=269-274&rft.issn=0344-5704&rft.eissn=1432-0843&rft.coden=CCPHDZ&rft_id=info:doi/10.1007/s00280-006-0266-x&rft_dat=%3Cproquest_cross%3E1192435411%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=213504465&rft_id=info:pmid/16763791&rfr_iscdi=true |